Pulmonary Disorders II

Hoeper MM, Benza RL, Corris P, et al. Intensive

care, right ventricular support and lung transplan-

tation in patients with pulmonary hypertension.

Eur

Respir

J.

2019;53(1):1801906.

https://doi.

org/10.1183/13993003.01906-2018

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/

ERS guidelines for the diagnosis and treatment of

pulmonary hypertension. Eur Heart J. 2022;43(38):3618-

3731. https://doi.org/10.1093/eurheartj/ehac237

Klose H, Chin KM, Ewert R, et al. Temporarily switch-

ing from oral to intravenous selexipag in patients with

pulmonary arterial hypertension: safety, tolerability, and

pharmacokinetic results from an open-label, phase III

study. Respir Res. 2021;22(1):34. https://doi.org/10.1186/

s12931-020-01594-8

Kovacs G, Bartolome S, Denton CP, et al. Definition,

classification and diagnosis of pulmonary hyperten-

sion. Eur Respir J. 2024;64(4):2401324. https://doi.

org/10.1183/13993003.01324-2024

Martin AK, Mercier O, Fritz AV, et al. ISHLT consen-

sus statement on the perioperative use of ECLS in lung

transplantation. Part II. Intraoperative considerations. J

Heart Lung Transplant. 2024:S1053-2498(24)01830-8.

https://doi.org/10.1016/j.healun.2024.08.027

McLaughlin VV, Shillington A, Rich S. Survival in

primary pulmonary hypertension: the impact of epo-

prostenol therapy. Circulation. 2002;106(12):1477-1482.

https://doi.org/10.1161/01.cir.0000029100.82385.58

Muzevich KM, Chohan H, Grinnan DC. Management

of pulmonary vasodilator therapy in patients with

pulmonary arterial hypertension during critical ill-

s13054-014-0523-z

Rich S, Brundage BH. High-dose calcium channel-

blocking therapy for primary pulmonary hypertension:

evidence for long-term reduction in pulmonary arte-

rial pressure and regression of right ventricular

hypertrophy. Circulation. 1987;76(1):135-141. https://doi.

org/10.1161/01.cir.76.1.135

Rich S, Kaufmann E, Levy PS. The effect of high doses

of calcium-channel blockers on survival in primary pul-

monary hypertension. N Engl J Med. 1992;327(2):76-81.

https://doi.org/10.1056/nejm199207093270203

Sahay S, Chakinala MM, Kim NH, Preston IR,

Thenappan T, Mclaughlin VV. Contemporary treatment

of pulmonary arterial hypertension: a U.S. perspec-

https://doi.org/10.1164/rccm.202405-0914so

Sitbon O, Humbert M, Nunes H, et al. Long-term intra-

venous epoprostenol infusion in primary pulmonary

hypertension: prognostic factors and survival. J Am Coll

Cardiol. 2002;40(4):780-788. https://doi.org/10.1016/

s0735-1097(02)02012-0

Torbic H, Tonelli AR. Sotatercept for pulmonary arte-

rial hypertension in the inpatient setting. J Cardiovasc

Pharmacol Ther. 2024;29:10742484231225310. https://

doi.org/10.1177/10742484231225310

Vaidy A, O’Corragain O, Vaidya A. Diagnosis and man-

agement of pulmonary hypertension and right ventricular

failure in the cardiovascular intensive care unit. Crit

Care Clin. 2024;40(1):121-135. https://doi.org/10.1016/j.

ccc.2023.05.003

Zamanian RT, Haddad F, Doyle RL, Weinacker AB.

Management strategies for patients with pulmonary

Med. 2007;35(9):2037-2050. https://doi.org/10.1097/01.

ccm.0000280433.74246.9e

Asthma Exacerbation

Althoff MD, Holguin F, Yang F, et al. Noninvasive

ventilation use in critically ill patients with acute

2020;202(11):1520-1530.

https://doi.org/10.1164/

rccm.201910-2021OC

American Thoracic Society. Proceedings of the ATS

workshop on refractory asthma: current understand-

ing, recommendations, and unanswered questions. Am

doi.org/10.1164/ajrccm.162.6.ats9-00

Camargo CA Jr, Spooner CH, Rowe BH. Continuous

versus

intermittent

beta-agonists

in

the

treat-

ment

of

acute

asthma.

Cochrane

Database

Syst

Rev.

2003;2003(4):CD001115.

https://doi.

org/10.1002/14651858.cd001115

D’Amato G, Vitale C, Molino A, et al. Asthma-related

deaths. Multidiscip Respir Med. 2016;11:37. https://doi.

org/10.1186/s40248-016-0073-0

Fanta

CH,

Rossing

TH,

McFadden

ER

Jr.

Glucocorticoids

in

acute

asthma.

A

critical